News

DP Clinical Announces Database Lock of its First COVID-19 Clinical Trial ROCKVILLE, MD

ROCKVILLE, MD – February 19, 2021 – DP Clinical, Inc., a privately held Contract Research Organization (CRO), announced the database lock of its first COVID-19 clinical trial. Taking place the United States, the goal of the study was to determine a suitable dosage of a drug candidate for the treatment of severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2).

“We are proud to have been selected as the CRO partner to run this study,” said Devinder Poonian, President and CEO of DP Clinical. “DP Clinical is a CRO with significant infectious disease experience, and we worked closely with this Sponsor to meet timelines while remaining flexible — essential to staying ahead of the virus. This was DP Clinical’s first COVID-19 trial, and the company expects more COVID-19-related projects in the near future as sponsors continue to seek out CROs with experience in this indication.”

Jim Hamer Elected to Unite 2 Fight Paralysis (U2FP) Board of Directors

ROCKVILLE, MD – February 16, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) located in Rockville, Maryland, announces James (Jim) Hamer, Director, Spinal Cord Injury (SCI) Programs, at DP Clinical has been elected to the Board of Directors for Unite 2 Fight Paralysis (U2FP) organization and will serve a three-year term. U2FP’s mission is to unite and empower the international spinal cord injury community to cure paralysis through advocacy, education, and support for research.

“With more than 24 years of SCI research and clinical trial experience, Jim will bring a critical perspective to the Board,” stated Devinder Poonian, President and CEO of DP Clinical.  “During his career, Jim has managed numerous acute and chronic SCI clinical trials including those with pharmaceuticals, autologous macrophages, the first in human sub-acute stem cell trials, as well as device studies.  DP Clinical started as an SCI CRO, and we look forward to witnessing one-day soon a curative therapy for this debilitating injury,” continued Ms. Poonian.

DP Clinical Supports the Maryland Tech Council’s COVID-19 Campaign

As a Rockville, Maryland-based company, DP Clinical has joined forces with other companies throughout the state to show support and unity as we work together to combat the COVID-19 pandemic. We have joined with the Maryland Tech Council to spread the word – “We come together in adversity. We put our heads down to solve complex issues. We do whatever it takes. We are truly #bettertogether!”

 

 

At DP Clinical, we continue to work tirelessly to help everyone stay safe while at the same time continuing to serve our study Sponsors, Investigator sites, patients, and DP Clinical staff.
 

DP Clinical COVID-19 Update

At DP Clinical, we are monitoring the evolving news around COVID-19 and following the best practices provided by health organizations. We want you to know that the health and well-being of our team and yours is of the utmost importance to us and is guiding our decisions during this unprecedented time. DP Clinical has implemented its business continuity procedures, and our staff is working remotely with all systems and services in place to ensure business proceeds without interruption.  We are working tirelessly to help everyone stay safe while at the same time continuing to serve you. 

Please know we are always available to you by email or phone.

This is a difficult time for all those directly and indirectly affected by COVID-19, and we will strive to make sure we are doing everything possible to minimize risk for our staff, vendors, sites, and particularly patients.

Kind regards,

The DP Clinical Team

NEWS RELEASE: DP Clinical-Supported Study Results in FDA Approval of ADMA Biologics’ ASCENIV™

ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics’ on the approval of ASCENIV™ (immune globulin intravenous, human – slra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. Click here to read more.

DP Clinical CEO Shares a CRO’s Perspective on Clinical Trial Evolution for Applied Clinical Trials

DP Clinical’s CEO, Devinder Poonian, was interviewed by Applied Clinical Trials for their June issue discussing a CRO’s perspective on the evolution of clinical trials. DP Clinical has been in business for more than 24 years, and Ms. Poonian shares her observations on industry changes, CRO size, and spinal cord injury trials. The article is available at http://www.appliedclinicaltrialsonline.com/clinical-trial-evolution-cro-s-perspective

DP Clinical Inaugural Member of the North American Spinal Cord Injury Consortium

DP Clinical Inaugural Member of the North American Spinal Cord Injury ConsortiumThe North American Spinal Cord Injury Consortium (NASCIC) has the mission to bring about unified achievements in research, care, and policy by fostering collaborative efforts across the spinal cord injury community. DP Clinical is an inaugural member of this important organization that brings together like-minded organizations, individuals, and groups to improve research, care, and policies impacting people living with spinal cord injury, families, and the community. Working collaboratively, the organization is structured to effectively bring out collective change through approved projects.

Events

Come meet the DP Clinical team at the following conferences: